samedan logo
home > ebr > autumn 2020 > fluidity one-w serum
European Biopharmaceutical Review

Fluidity One-W Serum

The ability to accurately characterise the immune response against coronavirus (SARS-CoV-2) is of vital importance in managing the current COVID-19 pandemic. Measuring antibody affinity under physiologically relevant conditions in complex mixtures, such as serum, remains challenging, but is critically important to furthering our understanding of the immune response and protection window in patients and vaccinated individuals. Using microfluidic diffusional sizing (MDS), we have characterised an anti-spike S1 antibody by measuring its binding affinity to the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein directly in serum.


In the quest to accurately identify individuals who are seropositive, as well as finding the most effective vaccines against the recently emerged SARS-CoV-2, it is fundamental to thoroughly characterise the immune response in the course of the infection or after vaccination. In particular, the virus-neutralising capacity of the immune system is of vital interest, and accurate tests to evaluate the affinity and quantity of neutralising antibodies (NAbs) in serum samples of COVID-19 patients or vaccinated individuals are key. Like other members of the coronavirus family, SARS-CoV-2 is a positive-sense single-stranded RNA virus that is predominantly made up of four main structural proteins: the envelope, membrane, nucleoprotein, and S proteins. The S protein is crucial for virus entry into the host cell. It is composed of two subunits: S1, which binds to the host cell receptor ACE2 (see Figure 1); and S2, which mediates the subsequent fusion of the virus with the cell membrane. Due to its key role mediating the first step of viral invasion of host cells, the RBD of S1 has proven to be the target of NAbs raised against other viruses of the corona family, and is likely to also be an important target in the case of SARS-CoV-2 (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Leading pharma packaging companies commit to supply for Covid-19 fight

The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed, and that no patient shall be left behind, no matter what region of the world they live in. Also, the companies will make every effort to support the pharma industry’s’ priorities for overall medication supply in addition to Covid-19 drugs. Each of the three companies manufactures billions of type-1 borosilicate glass vials, the most proven and most widely available material used to store and deliver vaccines around the world. They are making the statement to provide confidence in the global pharmaceutical supply chain in times of uncertainty.
More info >>

White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement